Semaglutide: A New GLP‐1 Analogue for Type 2 Diabetes

Prescriber - United Kingdom
doi 10.1002/psb.1784
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes

Pharmacy Today
2014English

Emerging Technologies to Achieve Oral Delivery of GLP-1 and GLP-1 Analogs for Treatment of Type 2 Diabetes Mellitus (T2DM)

Canadian Journal of Biotechnology
2017English

Clinical Potential of Treatment With Semaglutide in Type 2 Diabetes Patients

Drugs in Context
Molecular MedicinePharmacology
2019English

Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

"Type 1 on Type 2" Diabetes Mellitus: Autoimmune Type 1 Diabetes Superimposed on Established Type 2 Diabetes

Internal Medicine
Internal MedicineMedicine
2007English

Oral Semaglutide in the Management of Type 2 Diabetes: A Report on the Evidence to Date

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2019English

Ertugliflozin: A New SGLT2 Inhibitor for Type 2 Diabetes

Prescriber
Pharmacology
2019English

Combining SGLT2 Inhibitor and GLP-1 Agonist: Exaggerated Weight Loss in a Morbidly Obese Patient With Type 2 Diabetes

British Journal of Diabetes
2016English

Neprilysin Inhibition: A New Therapeutic Option for Type 2 Diabetes?

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy